NYSE · BSX
Boston Scientific Corporation
$42.69+$0.26 (+0.61%)
Boston Scientific Corporation’s quoted price sits in the lower half of its reported 52-week range, 59.59% below the high.
Loading market information…
NASDAQ · ANGO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
AngioDynamics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.19% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
AngioDynamics, Inc.’s next earnings report is currently expected on Jan 6, 2027, with estimated earnings per share of -$0.10. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow AngioDynamics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2025 | Jul 15, 2025 | -$0.03+76.92% vs estimate | $80.16M+7.95% vs estimate |
|---|
| Q3 2025 | Apr 2, 2025 | $0.03+123.08% vs estimate | $72.00M-3.03% vs estimate |
|---|
| Q2 2025 | Jan 8, 2025 | -$0.04+63.64% vs estimate | $72.85M+3.23% vs estimate |
|---|
THE ANALYST VIEW
11 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $19.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$42.69+$0.26 (+0.61%)
Boston Scientific Corporation’s quoted price sits in the lower half of its reported 52-week range, 59.59% below the high.
$198.34+$3.18 (+1.63%)
Becton, Dickinson and Company’s quoted price sits in the upper half of its reported 52-week range, 1.06% below the high.
$321.97+$3.66 (+1.15%)
Penumbra, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.16% below the high.
$141.39+$2.41 (+1.73%)
Teleflex Incorporated’s quoted price sits in the upper half of its reported 52-week range, 2.49% below the high.
$93.39+$1.18 (+1.28%)
Merit Medical Systems, Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.66% below the high.
$85.27+$2.40 (+2.9%)
LeMaitre Vascular, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.74% below the high.
$45.72-$0.04 (-0.09%)
CONMED Corporation’s quoted price sits in the upper half of its reported 52-week range, 14.8% below the high.
$12.83+$0.59 (+4.82%)
Integra LifeSciences Holdings Corporation’s quoted price sits in the lower half of its reported 52-week range, 37.38% below the high.
